Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp ADR (NQ: AMRN )

0.5590 +0.0390 (+7.50%)
Streaming Delayed Price Updated: 12:21 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amarin Corp ADR

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Amarin Reports Stable Revenue, Cash Position In Q1 But Lowers FY23 Operating Expense Guidance: What's Next?
Via Benzinga
Recap: Amarin Corp Q1 Earnings
Via Benzinga
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
From Amarin Corporation plc
Via GlobeNewswire
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
From Amarin Corporation plc
Via GlobeNewswire
Amarin Plc (AMRN) Q4 2022 Earnings Call Transcript
AMRN earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
Macro headwinds are weighing on risk-laden biotech stocks today. 
Via The Motley Fool
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
From Amarin Corporation plc
Via GlobeNewswire
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces Board Departures
From Amarin Corporation plc
Via GlobeNewswire
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
From Amarin Corporation plc
Via GlobeNewswire
Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome
Via Benzinga
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide
From Sarissa Capital Management LP
Via Business Wire
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
From Amarin Corporation plc
Via GlobeNewswire
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
From Amarin Corporation plc
Via GlobeNewswire
Amarin Sets the Record Straight on Sarissa’s Latest Misstatements
From Amarin Corporation plc
Via GlobeNewswire
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
Presentations on Additional REDUCE-IT® Sub-Population, In-Vitro Data on EPA to Be Featured at the Congress 
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Condemns Amarin Board for Frontrunning Results of Proxy Contest With Egregious Equity Grants to Executives
From Sarissa Capital Management LP
Via Business Wire
Amarin to Present at Cowen's 43rd Annual Health Care Conference
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Reminds Amarin Shareholders Today Is the Last Day to Vote “FOR” Change
From Sarissa Capital Management LP
Via Business Wire
Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Urges Amarin Shareholders to Vote “FOR” Necessary Change
From Sarissa Capital Management LP
Via Business Wire
Amarin Urges Shareholders to Vote “Against” Sarissa’s Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Urges Amarin Shareholders to Vote for Change and Remake Amarin for Shareholders
From Sarissa Capital Management LP
Via Business Wire
Sarissa Capital Blasts Amarin’s Repeated False Statements; Clearly Amarin Will Say Anything to Keep Sarissa Off the Board
From Sarissa Capital Management LP
Via Business Wire
Leading Independent Proxy Firm ISS Joins Glass Lewis in Recommending that Amarin Shareholders Vote “AGAINST” Sarissa’s Value-Destructive Proposals
From Amarin Corporation plc
Via GlobeNewswire
Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards
Sarissa Issued its False Release Hours After Receiving Confirmation That All Proxy Cards Were Being Accepted 
From Amarin Corporation plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.